Related references
Note: Only part of the references are listed.PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer
S. B. Dreyer et al.
CLINICAL ONCOLOGY (2020)
Pancreatic Cancer: From Genome Discovery to PRECISION-Panc
S. B. Dreyer et al.
CLINICAL ONCOLOGY (2020)
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Christopher Nevala-Plagemann et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response
Henry C-H Law et al.
CLINICAL CANCER RESEARCH (2020)
Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
Eric S Christenson et al.
LANCET ONCOLOGY (2020)
Carcinogenesis of Pancreatic Ductal Adenocarcinoma
Peter Storz et al.
GASTROENTEROLOGY (2020)
Molecular subtypes of pancreatic cancer
Eric A. Collisson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis
Simone Benitz et al.
GUT (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
An update on treatment options for pancreatic adenocarcinoma
Aurelien Lambert et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
A metabolomics-based biomarker signature discriminates pancreatic cancer from chronic pancreatitis
Eithne Costello
GUT (2018)
Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
Julia Mayerle et al.
GUT (2018)
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State
Anneleen Daemen et al.
CELL METABOLISM (2018)
Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance
Martin Wartenberg et al.
CLINICAL CANCER RESEARCH (2018)
Therapeutic developments in pancreatic cancer: current and future perspectives
John P. Neoptolemos et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
Gwen Lomberk et al.
NATURE COMMUNICATIONS (2018)
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Herve Tiriac et al.
CANCER DISCOVERY (2018)
The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer
Lumir Kunovsky et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
Molecular Profiling of Pancreatic Cancer Patients-Response
Michael J. Pishvaian et al.
CLINICAL CANCER RESEARCH (2018)
Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma
Ujjwal Mukund Mahajan et al.
GASTROENTEROLOGY (2018)
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features
Francesco Puleo et al.
GASTROENTEROLOGY (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
Kyaw L. Aung et al.
CLINICAL CANCER RESEARCH (2018)
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine
Lee Cheng Phua et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Elisabeth Hessmann et al.
GUT (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Andrew J. Aguirre et al.
CANCER CELL (2017)
Dissection of transcriptional and cis-regulatory control of differentiation in human pancreatic cancer
Giuseppe R. Diaferia et al.
EMBO JOURNAL (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A. Moffitt et al.
NATURE GENETICS (2015)
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors
Anneleen Daemen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Metabolomics in cancer biomarker discovery: Current trends and future perspectives
Emily G. Armitage et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2014)
Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
M. S. Monteiro et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Early diagnosis of pancreatic cancer: challenges and new developments
Sukhwinder Kaur et al.
BIOMARKERS IN MEDICINE (2012)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation
Mohit Jain et al.
SCIENCE (2012)
Metabolomics and Surgical Oncology: Potential Role for Small Molecule Biomarkers
Vanessa W. Davis et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
Trithorax group proteins: switching genes on and keeping them active
Bernd Schuettengruber et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Pancreatic Cancer
Manuel Hidalgo
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer
K. S. Goonetilleke et al.
EJSO (2007)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Establishing reporting standards for metabolomic and metabonomic studies: A call for participation
Oliver Fiehn et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2006)
Molecular markers of early pancreatic cancer
M Goggins
JOURNAL OF CLINICAL ONCOLOGY (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Metabolic profiles to define the genome: can we hear the phenotypes?
JL Griffin
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES (2004)
Share Paper
